Streetbeat News

MKGAF

Merck KGAA

https://www.merckgroup.com/

CEO

Stefan Oschmann

Industry

Medicinal and Botanical Manufacturing

Open

147.10

Mkt cap

64B

Volume

133

High

147.10

P/E Ratio

21.82

52-wk high

200.56

Low

147.10

Div yield

0.02

52-wk low

135.00

Merck KGaA's CEO stated that due to a recovery in sales growth, the company can afford to be cautious with mergers and acquisitions, given the high asset prices.

Portfolio Pulse from

January 23, 2025 | 3:00 pm

Merck KGaA held its Q3 2024 earnings call, discussing performance across its sectors: Healthcare, Life Science, and Electronics. Key executives and analysts participated, providing insights into the company's financial health and strategic direction.

Portfolio Pulse from

November 14, 2024 | 8:45 pm

CORRECTION: Merck KGaA Ticker Is 'MKGAF'.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 5:06 pm

Merck KGaA has decided to discontinue its Phase III trials of xevinapant in locally advanced head and neck cancer due to an interim analysis indicating the trial would not meet its primary objective. This decision affects both the TrilynX and X-Ray Vision studies.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 5:04 pm

Repligen Corporation (RGEN) has agreed to acquire Sweden-based Metenova, a move that is expected to expand Repligen's market reach and enhance its capabilities in fluid management. The acquisition is projected to contribute significantly to Repligen's revenues and margins from 2023 onwards. The deal is also expected to give Repligen a competitive edge against rivals like Merck KGaA (MKGAF, MKKGY).

Portfolio Pulse from Vandana Singh

September 26, 2023 | 7:07 pm

Merck KGa Germany reported a 4.8% decline in Q2 sales to €5.3 billion. Despite strong growth in the Healthcare sector, Group EBITDA pre declined by 12.8% to €1.55 billion due to decreased sales volumes and lower share of higher-margin products. The company has updated its 2023 forecast, expecting an organic sales growth of -2% to +2% and an organic decline in EBITDA pre by -9% to -3%. Both net sales and EBITDA pre are likely to be impacted by negative foreign exchange effects.

Portfolio Pulse from Vandana Singh

August 04, 2023 | 1:45 pm

The World Health Organization (WHO) has published new editions of the Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc), which include new medicines for various diseases. However, Novo Nordisk's obesity drug Saxenda was not included due to uncertain long-term clinical benefit and safety. Other drugs included in the list are from EMD Serono, Merck KGaA, Teva Pharmaceuticals, Roche Holdings, Ridgeback Biotherapeutics, and Regeneron Pharmaceuticals.

Portfolio Pulse from Vandana Singh

July 26, 2023 | 2:24 pm

Abcam is reportedly attracting takeover interest from Danaher, Agilent Technologies, and Germany's Merck KGaA, according to Bloomberg.

Portfolio Pulse from Happy Mohamed

June 30, 2023 | 4:26 pm

RBC Capital Markets has downgraded Abcam PLC (NASDAQ:ABCM) from Outperform to Sector Perform with a price target of $22, down from $23. The downgrade is due to activist investor engagement and potential bid anticipation, which may cause share volatility. Major players in the life science tools space, such as Thermo Fisher Scientific, Danaher Corporation, Merck KGaA, Agilent Technologies, Bio-Techne Corp, and Revvity Inc, could be interested in Abcam.

Portfolio Pulse from Vandana Singh

June 20, 2023 | 6:37 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.